Abivax S.A. Stock
Your prediction
Abivax S.A. Stock
Abivax S.A. gained 1.790% today.
Our community identified positive and negative aspects for Abivax S.A. stock for the coming years. 2 users see the criterium "Worthwhile Investment for the next years" as a plus for the Abivax S.A. stock. On the other hand our users think that "Valuation (undervalued/overvalued)" could be a problem in the future.
Pros and Cons of Abivax S.A. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
B****
?
C******** o* t** e**********
Cons
?
G***** c******* t* c**********
?
S********** s********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Abivax S.A. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Abivax S.A. | 1.790% | - | - | - | - | - | - |
| Valneva SE | -0.140% | 2.143% | -20.529% | -50.466% | -42.042% | -78.949% | -6.622% |
| Nanobiotix | 1.400% | -1.091% | -2.987% | -45.395% | -32.212% | -55.840% | -46.371% |
| Transgene S.A. | 5.390% | 0.594% | -0.392% | -39.739% | -24.179% | -58.866% | -46.806% |
Comments
DERFY stimmt der Outperform-Einschätzung der institutionellen Analysten zu
DERFY stimmt am 12.07.2016 der Outperform-Einschätzung der institutionellen Analysten mit dem Kursziel 26.97€ zu.News
EQS-News: Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024
EQS-News: Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024
EQS-News: Abivax Provides Update on Ulcerative Colitis Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease Mouse Model
EQS-News: Abivax Provides Update on Ulcerative Colitis Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease Mouse Model
EQS-News: Abivax presents first-half 2024 financial results
EQS-News: Abivax presents first-half 2024 financial results